Aclaris Therapeutics Inc (NASDAQ: ACRS) is 24.76% higher on its value in year-to-date trading and has touched a low of $0.59 and a high of $11.07 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACRS stock was last observed hovering at around $1.32 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $1.31, the stock is 7.62% and 12.08% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.13 million and changing -0.76% at the moment leaves the stock -27.39% off its SMA200. ACRS registered -87.75% loss for a year compared to 6-month loss of 11.02%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 15.93% gain in the last 1 month and extending the period to 3 months gives it a 6.50%, and is 3.97% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.06% over the week and 6.99% over the month.
Aclaris Therapeutics Inc (ACRS) has around 91 employees, a market worth around $93.35M and $31.12M in sales. Profit margin for the company is -248.28%. Distance from 52-week low is 121.96% and -88.17% from its 52-week high. The company has generated returns on investments over the last 12 months (-53.29%).
The EPS is expected to grow by 37.07% this year
The shares outstanding are 70.89M, and float is at 65.48M with Short Float at 6.02%.
Aclaris Therapeutics Inc (ACRS) Insider Activity
The most recent transaction is an insider purchase by Leonard Braden Michael, the company’s 10% Owner. SEC filings show that Leonard Braden Michael bought 123,017 shares of the company’s common stock on Jul 05 ’24 at a price of $1.15 per share for a total of $0.14 million. Following the purchase, the insider now owns 13.45 million shares.
Aclaris Therapeutics Inc disclosed in a document filed with the SEC on Jul 03 ’24 that Leonard Braden Michael (10% Owner) bought a total of 143,288 shares of the company’s common stock. The trade occurred on Jul 03 ’24 and was made at $1.16 per share for $0.17 million. Following the transaction, the insider now directly holds 13.32 million shares of the ACRS stock.
Still, SEC filings show that on Jul 02 ’24, Leonard Braden Michael (10% Owner) acquired 86,092 shares at an average price of $1.14 for $98489.0. The insider now directly holds 13,181,664 shares of Aclaris Therapeutics Inc (ACRS).
